Oncology Value Watchdog Report: Introduction to Value in Oncology: Definitions, Drivers, and Implications

Christina Corridon

  ( http://pages.zs.com/Oncology-WatchDog-Report-Issue-1-download-page.html )

> Download ( http://pages.zs.com/Oncology-WatchDog-Report-Issue-1-download-page.html )

The value of oncology drugs is of great interest to patients, physicians, payers and policymakers. Spending on oncology treatments is increasing faster as the number of cancer patients continues to increase and patients are living longer. In the U.S, health care reform efforts are bringing areas of high expense – like oncology drugs - under scrutiny. That means oncology manufacturers must prove the value of their products to many stakeholders.

The ZS Oncology Value Watchdog Report summarizes issues related to ongoing discussions about value. It provides insights about the definition of value, as well as frame works and perspectives for assessing value.

About the Expert

Christina Corridon is a Manager in the Boston office and a leader in the ZS Oncology Practice. She has over a decade experience working in the pharmaceutical and biotech industries, with specific expertise in oncology and biosimilars. During her consulting career she has worked on US and global projects spanning commercialization strategy including launch strategy and planning, go-to market strategy, commercial models, marketing strategy and brand planning. Christina has an MPH in Health Policy and Management from the UCLA Fielding School of Public Health and an MBA from the Stern School of Business at New York University focused in Marketing. Christina completed her BA at Cornell University.